YH4808 Postprandial PK/PD Study in Healthy Subjects

Phase 1 Completed 21 enrolled Yuhan Corporation

RandomizedCrossoverOpen-labelTreatment

Summary

A clinical Study to evaluate the safety and pharmacokinetics/pharmacodynamics(PK/PD) of YH4808 after repeated Oral administration and Postprandial state in healthy volunteers

Timeline

Start: 2012-11
Primary completion: 2013-02
Completion: 2014-02

Publications

Yoon S, Oh E, Park MS, Jang SB, Byun HM, Park H, Kim H, Kim CO. Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen. Transl Clin Pharmacol. 2021 Sep;29(3):150-159. doi: 10.12793/tcp.2021.29.e15. Epub 2021 Sep 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Esomeprazole	Small molecule	40 mg	—
Subject	YH4808	Other / unclassified	100 mg	Oral
Subject	YH4808	Other / unclassified	200 mg	Oral

Indications

No indication recorded.